Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $11.00 price target on the stock. HC Wainwright’s target price indicates a potential upside of 90.64% from the company’s previous close.
Several other research analysts have also commented on the stock. Raymond James initiated coverage on shares of Black Diamond Therapeutics in a report on Wednesday, July 31st. They issued an “outperform” rating and a $20.00 price target for the company. Piper Sandler reaffirmed an “overweight” rating and set a $12.00 target price on shares of Black Diamond Therapeutics in a research note on Wednesday, July 3rd. Finally, Wedbush reissued an “outperform” rating and issued a $16.00 price target on shares of Black Diamond Therapeutics in a research note on Wednesday, August 7th.
Check Out Our Latest Stock Analysis on BDTX
Black Diamond Therapeutics Stock Down 5.4 %
Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.03. On average, research analysts expect that Black Diamond Therapeutics will post -1.42 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the company. Ally Bridge Group NY LLC acquired a new stake in Black Diamond Therapeutics during the second quarter valued at approximately $3,891,000. Affinity Asset Advisors LLC acquired a new position in shares of Black Diamond Therapeutics in the 2nd quarter valued at $3,029,000. Bellevue Group AG increased its stake in Black Diamond Therapeutics by 4.9% in the 4th quarter. Bellevue Group AG now owns 8,535,839 shares of the company’s stock worth $23,986,000 after purchasing an additional 400,000 shares in the last quarter. TD Asset Management Inc lifted its stake in Black Diamond Therapeutics by 275.9% during the second quarter. TD Asset Management Inc now owns 266,312 shares of the company’s stock valued at $1,241,000 after buying an additional 195,464 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in shares of Black Diamond Therapeutics in the second quarter worth about $508,000. 95.47% of the stock is owned by institutional investors and hedge funds.
About Black Diamond Therapeutics
Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.
See Also
- Five stocks we like better than Black Diamond Therapeutics
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Marvell Technology AI Boom is Just Getting Started with ASIC
- Find and Profitably Trade Stocks at 52-Week Lows
- Trends Investors Should Watch This Quarter for Market Insights
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Homebuilders Poised for a Breakout: Top Stocks to Watch
Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.